6.
Lopetuso L, De Salvo C, Pastorelli L, Rana N, Senkfor H, Petito V
. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc Natl Acad Sci U S A. 2018; 115(40):E9362-E9370.
PMC: 6176569.
DOI: 10.1073/pnas.1803613115.
View
7.
Pietka W, Khnykin D, Bertelsen V, Lossius A, Stav-Noraas T, Fosse J
. Hypo-osmotic Stress Drives IL-33 Production in Human Keratinocytes-An Epidermal Homeostatic Response. J Invest Dermatol. 2018; 139(1):81-90.
DOI: 10.1016/j.jid.2018.07.023.
View
8.
Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T
. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010; 45(10):999-1007.
DOI: 10.1007/s00535-010-0245-1.
View
9.
Browning T, Trier J
. Organ culture of mucosal biopsies of human small intestine. J Clin Invest. 1969; 48(8):1423-32.
PMC: 322369.
DOI: 10.1172/JCI106108.
View
10.
Delpire E, Gagnon K
. Water Homeostasis and Cell Volume Maintenance and Regulation. Curr Top Membr. 2018; 81:3-52.
PMC: 6457474.
DOI: 10.1016/bs.ctm.2018.08.001.
View
11.
Brocker C, Thompson D, Vasiliou V
. The role of hyperosmotic stress in inflammation and disease. Biomol Concepts. 2012; 3(4):345-364.
PMC: 3438915.
DOI: 10.1515/bmc-2012-0001.
View
12.
Florholmen J, Johnsen K, Meyer R, Olsen T, Moe O, Tandberg P
. Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. BMC Gastroenterol. 2020; 20(1):321.
PMC: 7532085.
DOI: 10.1186/s12876-020-01447-0.
View
13.
Martin N, Martin M
. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016; 17(2):122-31.
DOI: 10.1038/ni.3370.
View
14.
Sedhom M, Pichery M, Murdoch J, Foligne B, Ortega N, Normand S
. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2012; 62(12):1714-23.
PMC: 3841767.
DOI: 10.1136/gutjnl-2011-301785.
View
15.
Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G
. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014; 8(10):1147-65.
DOI: 10.1016/j.crohns.2014.03.008.
View
16.
Dubois-Camacho K, Diaz-Jimenez D, De la Fuente M, Quera R, Simian D, Martinez M
. Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis. Front Immunol. 2019; 10:2449.
PMC: 6879552.
DOI: 10.3389/fimmu.2019.02449.
View
17.
Russo I, Zeppa P, Iovino P, Del Giorno C, Zingone F, Bucci C
. The culture of gut explants: A model to study the mucosal response. J Immunol Methods. 2016; 438:1-10.
DOI: 10.1016/j.jim.2016.07.004.
View
18.
Nnane I, Frederick B, Yao Z, Raible D, Shu C, Badorrek P
. The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis. Br J Clin Pharmacol. 2020; 86(12):2507-2518.
PMC: 7688540.
DOI: 10.1111/bcp.14361.
View
19.
Planell N, Lozano J, Mora-Buch R, Masamunt M, Jimeno M, Ordas I
. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2012; 62(7):967-76.
DOI: 10.1136/gutjnl-2012-303333.
View
20.
Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J
. Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770.
PMC: 6487890.
DOI: 10.1016/S0140-6736(16)32126-2.
View